DMD DiLab, Inc.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on February 14, 2008; DOI: 10.1124/dmd.107.019273


0090-9556/08/3605-911-915$20.00
DMD 36:911-915, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.019273v1
36/5/911    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Tian, X.
Right arrow Articles by Brouwer, K. L. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tian, X.
Right arrow Articles by Brouwer, K. L. R.

Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers

Xianbin Tian1, Brandon Swift, Maciej J. Zamek-Gliszczynski2, Martin G. Belinsky, Gary D. Kruh3, and Kim L. R. Brouwer

School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (X.T., B.S., M.J.Z.-G., K.L.R.B.); and Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania (M.G.B., G.D.K.)

The disposition of fexofenadine, a commonly used antihistamine drug, is governed primarily by active transport. Biliary excretion of the parent compound is the major route of systemic clearance. Previous studies demonstrated that fexofenadine hepatic uptake is mediated by organic anion transporting polypeptides. Recently, we showed that in mice fexofenadine is excreted into bile primarily by multidrug resistance-associated protein (Mrp) 2 (Abcc2). In the present study, the roles of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the hepatobiliary disposition of fexofenadine were examined in knockout mice using in situ liver perfusion. Compared with that in wild-type mice, basolateral excretion of fexofenadine was impaired, resulting in a ~50% decrease in perfusate recovery in Abcc3-/- mice; in contrast, fexofenadine hepatobiliary disposition was unaltered in Abcc4-/- mice. As expected, in Abcc2-/- mice, fexofenadine was redirected from the canalicular to the basolateral membrane for excretion. In Abcc2-/-/Abcc3-/- double-knockout mice, fexofenadine biliary excretion was impaired, but perfusate recovery was similar to that in wild-type mice and more than 2-fold higher than that in Abcc3-/- mice, presumably due to compensatory basolateral transport mechanism(s). These results demonstrate that multiple transport proteins are involved in the hepatobiliary disposition of fexofenadine. In addition to Mrp2 and Mrp3, other transport proteins play an important role in the biliary and hepatic basolateral excretion of this zwitterionic drug.


Address correspondence to: Dr. Kim L. R. Brouwer, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, C.B. #7360 Kerr Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360. E-mail: kbrouwer{at}unc.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.